Background:
Although epidemic, novel coronavirus (SARS-CoV-2) infection rarely affects pediatric
population. However, in the last months an increasing number of Italian pediatricians has reported the occurrence of
erythema pernio-like in children following a flu-like syndrome, after the outbreak of SARS-CoV-2 infection.
Objective:
To report cutaneous manifestation of SARS-CoV-2 infection in 4 adolescents.
Methods:
: Observational study reporting 4 adolescents with skin lesions, 2 weeks after the occurrence of a flu-like
syndrome.
Results:
Fourteen days after a flu-like syndrome, adolescents exhibited skin lesions to toes and feet. These lesions were
rounded, with blurred limits, with a 5-15 mm diameter, red-violaceous-bluish colored, sometimes resulting in bullous
lesions in correspondence of the central or apical portion, which tended to be covered with blackish crusts after evolution.
Lesions were also accompanied by pain of variable intensity and evolved within two or three weeks to self-resolution
without particular sequelae. In two patients, pharyngeal and nasal swabs were negative for SARS-CoV-2 infection, at the
presentation of skin lesions. After 2 months from clinical manifestations, patients were tested positive for SARS-CoV-2
antibodies.
Conclusions:
In pediatric and adolescent population, the occurrence of an erythema pernio-like after a flu-like syndrome
could be associated to SARS-CoV-2 infection.
The results of the study, confirmed also by self-assessment, allow us not only to state that the use of topical octatrienoic acid was effective and well tolerated for topical treatment of AKs leading to overall clinical improvement in approximately 90% of subjects treated for 60 days.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.